Skip to main content

Day 3 at the Supreme Court: Can the ACA Stand Without the Mandate?

March 28, 2012 — This morning's oral arguments in the Supreme Court case on the Affordable Care Act (ACA) revolved around a seemingly hypothetical question: If the high court were to invalidate the law's requirement for individuals to obtain health insurance, what happens to the rest of the law? Should it, too, be struck down?
The question seems less hypothetical, however, after yesterday's 2-hour hearing on the individual mandate. The proceedings led some legal experts to say that the court's 5-member conservative majority, based on the skepticism it exhibited, could very well void the mandate as a Congressional infringement on individual liberty.
Attorney Paul Clement, representing the 26 state officials and the National Federation of Independent Business (NFIB) in their challenge of the law, told the justices that if the individual mandate is deemed unconstitutional, "the rest of the act cannot stand."
Paul Clement
"What you would end up with is a hollow shell," said Clement. He said the court should erase the entire law and give Congress a "clean slate" for enacting healthcare reform.
US Deputy Solicitor General Edwin Kneedler conceded that a few key ACA provisions would need to go if the individual mandate is voided. However, he also argued that most of the law should remain intact, particularly as Americans are already benefiting from some of its reforms, such as keeping young adults on their parents' health plans up to age 26 years. They would lose that coverage, he warned, if the court invalidated the law from A to Z.
Justice Antonin Scalia
As in the ACA hearings on Monday and Tuesday this week, all of the justices, with the exception of Justice Clarence Thomas, jumped into the opposing attorneys' presentations with questions and, seemingly, opinions. Justice Antonin Scalia, a member of the court's conservative wing, seemed to show his hand on the severability issue when he said, "My approach would say if you take the heart out of the statute, the statute's gone."
Justice Sonia Sotomayor
In contrast, Justice Sonia Sotomayor, a member of the court's more liberal wing, suggested that the justices could preserve the ACA if the court voids the mandate and lets Congress amend it with other provisions that would accomplish the mandate's objective.
"So if we strike just a tool, why should we strike the whole act, when Congress has other tools available?" Sotomayor asked. "What's wrong with leaving it...in the hands of the people who should be fixing this, not us?"
Only 1 Lower Court has Struck Down Entire Law
Opponents of the ACA have challenged it in more than 2 dozen federal lawsuits, and lost most of them. Only once have they convinced a court to declare the entire law unconstitutional. That happened in the case that officials from 26 states and the NFIB filed in a district court in Pensacola, Florida. There, US District Judge Roger Vinson voided the mandate as overstepping Congress' Constitutional authority to regulate commerce, and as he viewed the mandate as "inextricably bound" to the law's remaining provisions, he then canned the entire ACA.
An appeals court in Atlanta, Georgia, also declared the mandate unconstitutional, but said the rest of the ACA could stand. That appellate ruling is now under review by the Supreme Court, which will settle the severability matter once and for all.
Government Says Most of Law Does Not Affect States, NFIB
To convince the high court that the mandate and ACA are "inextricably bound," Clement today cited the government's own argument that the law's dramatic health insurance reforms hinge on everyone obtaining coverage. Absent any mandate, the government contends, it would be counterproductive to require private insurers to guarantee coverage to everyone and base premiums on "community rating"; that is, on age, geographic area, family size, and tobacco use, but not on preexisting conditions.
The reason? Healthy Americans could wait until they were seriously ill before they applied for their guaranteed insurance, leaving private insurers in the meantime with a risk pool of sick and expensive individuals. This "adverse selection" would force insurers to raise premiums to unaffordable levels for an ever-shrinking number of customers, and the private health insurance industry would wither, according to the government.
The state officials and the NFIB have noted that the ACA bears ample evidence that Congress viewed the mandate as pivotal and indispensable. In addition, an early healthcare reform bill in Congress featured a severability clause to prevent 1 unconstitutional apple from spoiling the barrel, but that clause is missing in the enacted law.
In response, Deputy Solicitor General Kneedler said today that the state officials and the NFIB are not affected by most of the ACA's provisions, and therefore lack a good reason to seek their overthrow if the mandate is voided. Kneedler disagreed that Congress viewed the ACA as an all-or-nothing proposition. However, if the high court were to declare the mandate unconstitutional, said Kneedler, it should only abolish guaranteed coverage and community rating, not the entire law.
"Friend of Court" Says Reforms Could Work Minus Mandate
Stepping into the legal ring today with the Obama administration and the ACA's challengers was attorney H. Bartow Farr III. The court appointed Farr as a "friend of the court," or amicus curiae, to argue that the rest of the law could stand if the mandate is gaveled down.
H. Bartow Farr III
Farr disagreed with the government's position that guaranteed coverage and community rating would backfire minus the mandate. He cited a Congressional Budget Office study stating that ACA premium subsidies would encourage a broad range of Americans to obtain coverage, and thus mitigate the effects of adverse selection. The ACA also has other provisions that would bring healthy people into the insurance risk.
Invalidating the entire law, Farr said today, "is an example of the best driving out the good."
Even without the mandate, the ACA "would still open the insurance market to millions of people and lower premiums for millions," said Farr.
The high court holds its last hearing on the historic ACA case this afternoon. The justices will listen to oral arguments, and freely interrupt with questions, on the constitutionality of Medicaid expansion that the law sets in motion. The court will issue a ruling in the case sometime before July.

Authors and Disclosures

Journalist

Robert Lowes

Robert Lowes is a journalist for Medscape Medical News. A former senior editor at Medical Economics magazine and contributor to numerous healthcare publications, Robert has covered medicine from almost every conceivable angle — public policy, managed care, education, ethics, medical malpractice, information technology, billing and collections, waiting-room design, and first-degree murder. His articles have won major awards such as first place in the annual journalism competition of the National Institute for Health Care Management, and several have been republished in books. Robert also is an anthologized poet. He can be contacted at rlowes@medscape.net.

Robert Lowes has disclosed no relevant financial relationships.

Comments

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...